FSFarid Salih

Farid Salih

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Farid Salih has a total of 163 co-authors. Here are the top co-authors by number of shared publications:

  • Stefan Wolf

    Department of Neurosurgery, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany

    6 shared publications
  • Florian Masuhr

    Dept. of Neurology, Bundeswehrkrankenhaus Berlin, Scharnhorststraße 13, 10115 Berlin, Germany

    4 shared publications
  • Olaf Hoffmann

    Dept. of Neurology, St. Josefs-Krankenhaus, Allee nach Sanssouci 7, 14471 Potsdam, Germany; Medizinische Hochschule Brandenburg Theodor Fontane, Fehrbelliner Straße 38, 16816 Neuruppin, Germany

    4 shared publications
  • Albrecht Günther

    Department of Neurology, University Hospital Jena, Jena, Germany

    3 shared publications
  • Christoph Rosenthal

    Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin (Interdisziplinäre Neurointensivstation), Charite-Universitätsmedizin Berlin

    3 shared publications
  • Florian Weissinger

    Dept. of Neurology, Vivantes Humboldt-Klinikum, Am Nordgraben 2, 13509 Berlin, Germany

    3 shared publications

Latest Publications

  • Open Access

    Religion and Religiosity in End-of-Life Decisions in Neurocritical Care

    by Hannah M. Tempel, Stefan Wolf, Farid Salih

    Objectives: End-of-life decisions are shaped by diverse biographical, social, and cultural factors. Few studies have systematically examined the impact of religion on end-of-life decisions, and even less data are available on religiosity (i.e., strength of religious faith). The Religion and religiosity in End-of-life deCisiOns in neuroCritIcaL carE (RECONCILE) study aimed to investigate whether religiosity, rather than religion, plays a decisive role in shaping end-of-life decisions. Design: Prospective observational study. Setting: The study was conducted between 2021 and 2024 at two neuro-ICUs at Charité—Universitätsmedizin Berlin. Patients: We prospectively studied patients with acute brain injury and poor neurologic prognosis defined by the absence of regaining decision-making capacity or sufficient autonomy. A total of 100 patients were included. Interventions: None. Measurements: Relatives were consulted to ascertain the patients’ presumed wishes regarding the continuation or withdrawal of life-sustaining intensive care. The 10-item Santa Clara Strength of Religious Faith questionnaire was applied to measure the patient´s religiosity on a scale between 10 and 40 points. We applied the t -test for independent variables to evaluate the influence of religiosity on end-of-life decisions. To adjust for possible confounders like age, sex, nationality, and religion, we calculated a logistic regression as well as an analysis of variance calculation. Main Results: In patients in whom intensive care was continued, the median score was significantly higher compared with patients in whom intensive care was withdrawn (28.1 ± 9.0 vs. 20.5 ± 8.3; p < 0.001; Cohens d = 0.875). This finding was reproduced in each denominational group. Religion, age, and sex showed no significant association with the end-of-life decision behavior. Germans chose withdrawal of therapy significantly more often than non-Germans ( p = 0.01) but also showed significantly lower religiosity scores (21.9 vs. 27.9; p = 0.003). Conclusions: The RECONCILE study demonstrates that religiosity looks more important in influencing end-of-life decisions than religion. Higher levels of religiosity were associated with a preference for more aggressive treatment, even when neurologic prognosis is poor .

  • Open Access

    Prognosis of acute symptomatic seizures and impact of prolonged treatment with anti‐seizure medication

    by Hannah Traben, Julia Herzig-Nichtweiß, Lisa Langenbruch, Felix Kohle, Johann O. Pelz, Piergiorgio Lochner, Matthias Wittstock, Albrecht Günther, Angelika Alonso, Marko Blickhan, et al.

    Objectives: Acute symptomatic epileptic seizures (ASySs) occur in temporal proximity to acute brain insults. Given their low risk of subsequent unprovoked seizures, current guidelines recommend either no treatment with anti‐seizure medication (ASM) or early discontinuation, yet ASM treatment is often continued beyond hospital discharge. We aimed at investigating the cumulative 3‐year risk and predictors of unprovoked seizures after ASySs and assessing the effect of ASM treatment duration. Methods: The prospective, multicenter register on the prognosis of acute symptomatic seizures (PROSE register) recruited adults with clinically apparent, acute symptomatic, first‐ever epileptic seizure, excluding status epilepticus. Primary endpoint was occurrence of a first unprovoked seizure. The impact of ASM treatment duration was assessed through a Cox regression correcting for treatment selection bias. The chance of occurrence of a seizure in the next year (COSY) was calculated to evaluate driving eligibility. Results: The 3‐year cumulative incidence of unprovoked seizures was 14% [95% confidence interval (CI): 7%–21%] among 122 participants with structural etiologies. Male sex (hazard ratio [HR] 9.3; 95% CI 1.9–45.1), early epileptiform electroencephalography (EEG) activity (HR 7.4; 95% CI 1.8–31.1), and latency ≥48 h between onset of underlying condition and ASyS (HR 4.8; 95% CI 1.3–18.1) were independently associated with unprovoked seizures. ASM treatment duration had no apparent effect (HR 1; 95% CI 1–1; p = .84). The initial COSY was 10% and fell below 2% within 2 years. Significance: Even in structural etiologies, ASySs bear a relatively low risk of later unprovoked seizures. There is still no evidence favoring prolonged ASM treatments. These findings may help preventing ASM overtreatment and guide counseling on driving eligibility.

  • Open Access

    Brain death determination in patients with veno-arterial extracorporeal membrane oxygenation: A systematic study to address the Harlequin syndrome

    by Farid Salih, Johann Lambeck, Albrecht Günther, Caroline Ferse, Olaf Hoffmann, Konstantinos Dimitriadis, Andre Finn, Stephan A. Brandt, Benjamin Hotter, Florian Masuhr, et al.


  • Open Access

    Computed tomography angiography in the diagnosis of brain death: Implementation and results in Germany

    by Olaf Hoffmann, Farid Salih, Florian Masuhr

    Background: Computed tomography angiography (CTA) has been investigated as a confirmatory study (CS) for the diagnosis of brain death (BD). International consensus regarding its use, study parameters, and evaluation criteria is lacking. In the German BD guideline, a CTA protocol was first introduced in 2015.Methods: The authors obtained a comprehensive dataset of all BD examinations in adults from the German organ procurement organization to investigate implementation, results, and impact of CTA on BD determination during the first 4 years.Results: In 5152 patients with clinically absent brain function, 1272 CTA were reported by 676 hospitals. Use of CTA increased from 17.2% of patients in the first year to 29.7% in the final year. CTA replaced other CS such as electroencephalography without increasing overall CS frequency. Technical failure was rare (0.9%); 89.3% of studies were positive. Negative results (9.8%) were more frequent with secondary brain injury, longer duration of the clinical BD syndrome, or unreliable clinical assessment. Median time to diagnosis was longer with CTA (2.6 h) versus other CS (1.6 h). CTA had no differential impact on the rate of confirmed BD and did not improve access of small hospitals to CS for BD determination.Conclusions: CTA expands the range of available CS for the diagnosis of BD in adults. Real‐world evidence from a large cohort confirms usability of the German CTA protocol within the guideline‐specified context.


  • Open Access

    Prognosis and management of acute symptomatic seizures: a prospective, multicenter, observational study

    by Julia Herzig-Nichtweiß, Farid Salih, Sascha Berning, Michael P. Malter, Johann O. Pelz, Piergiorgio Lochner, Matthias Wittstock, Albrecht Günther, Angelika Alonso, Hannah Fuhrer, et al.


  • Immunvermittelte Sinus- und Hirnvenenthrombosen: VITT und prä-VITT als Modellerkrankung

    by Farid Salih, Linda Schönborn, Matthias Endres, Andreas Greinacher

    In diesem Übersichtsartikel beschreiben wir die klinischen und paraklinischen Charakteristika der Vakzin-induzierten immunthrombotischen Thrombozytopenie (VITT) und fassen den gegenwärtigen Kenntnisstand zur Pathogenese zusammen. Bei der VITT bilden sich 5–20 Tage nach einer Impfung mit einem Adenovirus-vektorbasiertem SARS-CoV-2-Vakzin (AstraZeneca oder Johnson & Johnson) lebensbedrohliche Thrombosen aus, vor allem in den zerebralen Sinus und Hirnvenen. Laborchemisch zeigt sich eine typische Thrombozytopenie mit erhöhten D-Dimeren. Der Pathogenese liegen immunologische Prozesse zugrunde, die Ähnlichkeiten mit der Heparin-induzierten Thrombozytopenie aufweisen: so geht die VITT mit hochtitrigem Immunoglobulin G gegen das thrombozytäre Protein Plättchenfaktor 4 (PF4) einher. Durch die Interaktion mit dem Impfstoff wird PF4 so verändert, dass es von Antikörper-produzierenden Zellen des Immunsystems erkannt wird. Die so produzierten Anti-PF4-Antikörper führen über thrombozytäre FcγIIa-Rezeptoren zu einer Plättchenaktivierung. Der Nachweis plättchenaktivierender Anti-PF4-Antikörper bestätigt die Diagnose einer VITT. Antikoagulanzien, die die Bildung von Thrombin oder Thrombin selbst blockieren und hochdosiertes i. v.-Immunglobulin G, das die Fcγ-Rezeptor-vermittelte Zellaktivierung inhibiert, stellen die wirksame und kausale Behandlung der VITT dar. Bei Patienten mit katastrophalem Verlauf kann ein Plasmaaustausch versucht werden. Bei einigen Patienten ist ein prä-VITT Syndrom als Prodromalstadium zu beoachten, das sich typischerweise mit Kopfschmerzen manifestieren kann und dessen frühe Behandlung hilft, thrombotische Komplikationen zu vermeiden. Die spezifische Dynamik der VITT-assozierten Immunreaktion entspricht einer transienten, sekundären Immunantwort. Aktuelle Studien gehen der Frage nach, wie PF4 an unterschiedliche adenovirale Proteine bindet und beleuchten die Rolle von anderen Impfstoff-Bestandteilen als potentielle Liganden für die PF4-Bindung. Einige dieser Faktoren sind auch an der Etablierung eines proinflammatorischen Milieus („danger signal“) beteiligt, das unmittelbar nach der Impfung die 1. Phase der VITT-Pathogenese triggert. Sobald in der 2. Phase der VITT-Pathogenese hohe Titer von Anti-PF4-Antikörper gebildet sind, aktivieren diese neben Thrombozyten auch Granulozyten. In einem als NETose (von „neutrophil extracellular traps“) bezeichneten Prozess setzen aktivierte Granulozyten dabei DNA frei, mit der PF4 weitere Komplexe bildet, an die Anti-PF4-Antikörper binden. Dies verstärkt die Fcγ-Rezeptor-vermittelte Zellaktivierung weiter mit der Folge einer ausgeprägten Thrombin-Bildung. Zum Ende des Artikels geben wir einen Ausblick, welchen Einfluss die bisherigen Erkenntnisse zur VITT auf weitere globale Impfkampagnen gegen SARS-CoV-2 haben und beleuchten, wie Anti-PF4-Antikörper jenseits von VITT und HIT auch eine Rolle bei seltenen Erkrankungen spielen, die mit rezidivierenden venösen und arteriellen Thrombosen einhergehen. In this review, we summarise the current knowledge on vaccine-induced immune thrombotic thrombocytopenia (VITT) and new insights into its underlying pathogenesis. VITT is characterised by severe thromboses occurring 5–20 days after vaccination with an adenoviral vector-based SARS-CoV-2 vaccine (AstraZeneca or Johnson & Johnson). Thromboses typically involve the cerebral sinus and venous system. Routine laboratory analyses show thrombocytopenia and high D-dimer levels. The pathogenesis is based on immunological processes similar to those in heparin-induced thrombocytopenia. Accordingly, VITT is associated with high-titre immunoglobulin G directed against platelet factor 4 (PF4). Interaction with adenoviral vector-based vaccines leads to modifications of PF4 allowing antibody-producing cells to identify PF4. Anti-PF4 antibodies activate platelets through FcγIIa receptors. The detection of platelet-activating anti-PF4 antibodies confirms the diagnosis of VITT. Treatment is based on anticoagulation, which inhibits thrombin itself or thrombin formation, and high-dose intravenous immunoglobulin G, which inhibits cell activation via FcγIIa receptors. In severe cases, plasma exchange could also be an option. In some patients, a pre-VITT syndrome precedes VITT. Pre-VITT patients typically present with severe headache before thromboses are manifest. The early identification of a pre-VITT syndrome allows for the prevention of thrombotic complications. The specific dynamics of the immune reaction in VITT correspond to a transient, secondary immune response. Current studies address how PF4 binds to different adenoviral proteins and investigate the functional role of other vaccine components. Some of these factors contribute to the induction of a pro-inflammatory “danger signal” that triggers the first stage of VITT pathogenesis. In the second stage, high-titre anti-PF4 antibodies activate platelets and granulocytes. In a process called NETosis (“neutrophil extracellular traps”), activated granulocytes release DNA. Anti-PF4 antibodies then bind to complexes of PF4 and DNA. This enhances further cell activation via Fcγ receptors and consequently also the formation of thrombin. At the end of the article, we comment on how the current knowledge on VITT may influence global vaccination campaigns against SARS-CoV-2 and we address how anti-PF4 antibodies may be involved in recurrent arterial and venous thromboses not associated with VITT and HIT. Article published online: 02 November 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Open Access

    Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway

    by Farid Salih, Siegfried Kohler, Linda Schönborn, Thomas Thiele, Andreas Greinacher, Matthias Endres

    Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but highly morbid complication after adenoviral vector-based SARS-CoV-2 vaccination. The pre-VITT syndrome is defined as vaccine-induced immune thrombocytopenia without thrombosis typically presenting with new-onset headache. This review aims to identify at-risk patients before complications such as cerebral venous sinus thrombosis occur. We review previously published reports of 19 patients (median age 35 years, range 23–74; 16 females) who met the diagnostic criteria for a pre-VITT syndrome. Seven patients progressed to VITT, 12 patients did not. Patients who experienced VITT received delayed treatment. The median interval between the onset of headache and VITT-treatment (i.e. anticoagulation, immune globulins, or corticosteroids) was 5 days (range 1–8 days) compared with 2 days (0–5 days) in those without subsequent VITT (P = 0.033). The interval from onset of headache to anticoagulation was longer in patients with VITT (median 7 vs. 2 days; range 3–9 vs. 0–7 days; P = 0.01). Anticoagulation was safe in all patients with a pre-VITT syndrome as no haemorrhagic complications occurred after anticoagulation was started despite low platelets. The transient decline of platelet count after admission was significantly more pronounced in patients who progressed to VITT (median 67 vs. 0 × 103/µL; range 0–77 × 103/µL vs. 0–10 × 103/µL; P = 0.005). d-dimers did not differ between groups. Pre-VITT syndrome is a ‘red flag’ and allows to identify and preemptively treat patients at-risk of further progression to VITT. However, it must be distinguished from post-vaccination immune thrombocytopenia.


  • Aktuelle Aspekte in der Intensivtherapie des Schlaganfalls

    by Farid Salih, Alexandra Becker, Nicolai Andrees, Hannah Tempel

    In Deutschland erleiden jährlich ca. 270000 Patient*innen einen Schlaganfall [1]. Die Invaliditäts- und Mortalitätsraten sind hoch (bis zu 30%) und ein relevanter Anteil der Betroffenen muss auf der Intensivstation behandelt werden. Der Artikel thematisiert intensivmedizinische Behandlungsaspekte des ischämischen Schlaganfalls als häufigste Unterform (85% aller Schlaganfälle). In this review, we provide an update on the intensive care unit (ICU) management of ischemic stroke. Over the last decade, new evidence has led to rapid changes in the early management of patients admitted with acute ischemic stroke. Nevertheless, stroke remains a leading cause of disability. Consequently, a significant number of patients with acute ischemic stroke require ICU level care. The most frequent reasons for ICU admissions are large infarction with potential swelling, reduced level of consciousness, secondary hemorrhagic transformation, acute symptomatic seizures or respiratory failure and stroke-related disorders of the brain–heart interaction. Moreover, there is an increasing number of patients receiving intravenous thrombolysis or mechanical thrombectomy with a subsequent need of ICU monitoring. Several studies have shown that the implementation of specialized neuro-intensive care teams help to improve functional outcome after acute ischemic stroke. The main goal in the ICU management of stroke patients is to prevent secondary brain injury. To this end, a comprehensive approach to optimize systemic physiological homeostasis, control intracranial pressure, cerebral perfusion, hemodynamic and respiratory parameters is needed. Here, we summarize recent advances in invasive and non-invasive neuro-monitoring, decision making in decompressive neurosurgery for large supratentorial or cerebellar infarction, specific cardiorespiratory management, nutrition, temperature management and mobilization strategies in ischemic stroke. Article published online: 23 March 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Open Access

    IGNITE Status Epilepticus Survey: A Nationwide Interrogation about the Current Management of Status Epilepticus in Germany

    by Christina M. Kowoll, Matthias Klein, Farid Salih, Gereon R. Fink, Henning R. Stetefeld, Oezguer A. Onur, Michael P. Malter, on behalf of the IGNITE Group

    We aimed to evaluate the current management of status epilepticus (SE) in intensive care units (ICUs) in Germany, depending on the different hospital levels of care and the ICU specialty. We performed a nationwide web-based anonymized survey, including all German ICUs registered with the German Society for Neurointensive and Emergency Care (Deutsche Gesellschaft für Neurointensiv- und Notfallmedizin; DGNI). The response rate was 83/232 (36%). Continuous EEG monitoring (cEEG) was available in 86% of ICUs. Regular written cEEG reports were obtained in only 50%. Drug management was homogeneous with a general consensus regarding substance order: benzodiazepines—anticonvulsants—sedatives. Thereunder first choice substances were lorazepam (90%), levetiracetam (91%), and propofol (73%). Data suggest that network structures for super-refractory SE are not permeable, as 75% did not transfer SE patients. Our survey provides “real world data” concerning the current management of SE in Germany. Uniform standards in the implementation of cEEG could help further improve the overall quality. Initial therapy management is standardized. For super-refractory SE, a concentration of highly specialized centers establishing network structures analogous to neurovascular diseases seems desirable to apply rescue therapies with low evidence carefully, ideally collecting data on this rare condition in registries and clinical trials.